Fig. 3

Slc25a1 inhibition attenuates high-fat diet (HFD)-induced hyperglycemia by increasing glucose uptake but not use. A: plasma glucose levels (n = 5–6). B: plasma insulin levels (n = 6). C: glucose tolerance test of zebrafish (n = 5–6). D: mRNA expression of hepatic chrebp, glut2, and insrb in zebrafish (n = 5–7). E: hepatic glycogen in zebrafish (n = 6). F: hepatic glycolysis-related metabolites in zebrafish, n = 4. G: mRNA expression of hepatic pfk and pk in zebrafish (n = 5–7). H: mRNA expression of hepatic ldha, ldhba, and ldhbb in zebrafish (n = 5–7). I: mRNA expression of hepatic pca and pcb in zebrafish (n = 5–7). J and K: protein expression of hepatic Pdk4 and p-Pdhe1α in zebrafish and Nile tilapia (n = 2–3). L: rate of d-[1-14C]-glucose oxidation in primary hepatocytes of Nile tilapia (n = 3). M: glucose metabolism patterns after inhibition of Slc25a1 under HFD. Values are means ± SD. The asterisk symbol indicates significant differences from the control treatment at *P < 0.05, **P < 0.01, ***P < 0.001 (independent-sample t test). Figure created with BioRender.com.